Table 1.

Efficacy of Lead Agents across Model Systems

Agent	FRT G542X TECC Gt (mS/cm2) (Mean ± SE)	FRT UGAC Dual-Luciferase Firefly/Renilla (Mean ± SD)	FRT G542X HRP RLU (Mean ± SE)	HBE G542X/ΔF508 HBE Ussing Chamber Isc (μA/cm2) (Mean ± SE)
Colchicine	0.21 ± 0.0*†	1.28 ± 0.0.008	36000 ± 1554*	1.2 ± 0.2†
Cyclohexamide	0.13 ± 0.06‡§	1.81 ± 0.01	38171 ± 1618*	3.4 ± 0.07§
Oxibendazole	0.16 ± 0.005*||	1.34 ± 0.01	28150 ± 908.6¶	1.36 ± 0.04||
Pyronaridine tetraphosphate	0.13 ± 0.08#	1.1 ± 0.005	1091 ± 98.8	6.2 ± 0.3‡
Prednicarbate	0.14 ± 0.02¶	0.89 ± 0.0034	10515 ± 870.2	4.9 ± 1.2#
Escin	0.20 ± 0.001*	2.04 ± 0.02	57402 ± 2836*	7.1 ± 0.3*
Potassium paraamino benzoic acid	0.14 ± 0‡||	1.44 ± 0.02	10811 ± 701.1	6.6 ± 1.2‡||
Doxorubicin	0.11 ± 0.01	1.99 ± 0.007	26269 ± 1426¶	2.38 ± 0.14

Definition of abbreviations: FRT = Fischer rat thyroid; HBE = human bronchial epithelial; HRP = horseradish peroxidase; Isc = short circuit current; RLU = relative light units; TECC = transepithelial chloride conductance.

Assays included TECC (Gt; mean values ± SE; mS/cm²), dual-luciferase (Firefly/Renilla ratio; mean ± SD), and HRP-detected protein expression (RLU; mean ± SE), each using FRT cells; and Ussing chamber analysis using primary HBE cells (Isc; mean ± SE; μA/cm²). Unless indicated, these compounds were treated at 10 μM. Concentration = 10 μM unless otherwise indicated.

^*P < 0.0001.

^†1 μM.

^‡P < 0.01.

^§3 μM.

^||30 μM.

^¶P < 0.001.

^#P < 0.05.